• Johannes Schetelig on remission induction versus immediate allogeneic HSCT for patients with AML

  • Jul 16 2024
  • Length: 14 mins
  • Podcast

Johannes Schetelig on remission induction versus immediate allogeneic HSCT for patients with AML

Listen for free

View show details

  • Summary

  • Professor Johannes Schetelig joins us to discuss the results of the ASAP phase 3 trial comparing remission induction with immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia.

    Read the full article:
    https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00065-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    Show more Show less
Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about Johannes Schetelig on remission induction versus immediate allogeneic HSCT for patients with AML

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available